Trial Profile
A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs APVO-414 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics; Emergent Product Development Gaithersburg
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to complete enrollment of Phase 1 dosing cohorts in Q3 2018 and report preliminary data in Q4 2018.